Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may require biologics, such as mepolizumab,...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2025-05-01
Serie:	Journal of Allergy and Clinical Immunology: Global
Ämnen:	Asthma mepolizumab concentration
Länkar:	http://www.sciencedirect.com/science/article/pii/S2772829325000116
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!